Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon α2b for reversal of HPV infection after cervical HSIL conization
ChiCTR2600117050Phase 4Completed
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of interferon alfa-2b in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Positive rate of human papillomavirus infection. Started Jan 2026; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2600117050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117050.